文献速递糖尿病

日本单基因糖尿病的遗传与临床特征:日本糖尿病学会全国研究

Genetic and Clinical Characteristics of Monogenic Diabetes in Japan: A Nationwide Study by the Japan Diabetes Society.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究纳入232例35岁前起病、BMI<30 kg/m²且胰岛自身抗体阴性的先证者,对11个致病基因进行靶向测序。67例(28.9%)检出致病或可能致病(P/LP)变异,其中64例(95.5%)为可指导治疗的可操作基因变异。经典筛查标准和MODY概率计算器均不能识别所有单基因糖尿病病例。

要点

  • 28.9%的先证者检出P/LP变异,95.5%位于可操作基因。
  • 52.2%的P/LP携带者不符合经典筛查标准。
  • MODY概率评分在P/LP携带者中更高,但早期胰岛素治疗会显著降低评分。

核心结论

  • 建立了全国性基因检测平台并识别出可操作变异携带者,为精准医学提供可能。
  • 经典筛查标准和MODY概率计算器均不能识别所有单基因糖尿病病例,需要更广泛的基因检测。

研究设计与样本

  • 研究纳入232例先证者,起病年龄<35岁、BMI<30 kg/m²、胰岛自身抗体阴性,招募时间为2019至2024年。
  • 对11个致病基因进行靶向测序,必要时行多重连接依赖探针扩增(MLPA)。

主要发现

  • 67例(28.9%)检出P/LP变异:GCK 25例、HNF1A 22例、HNF1B 7例、HNF4A 6例、ABCC8 4例、NEUROD1/PDX1/INSR各1例。
  • 64例(95.5%)的P/LP变异位于可能影响治疗策略的可操作基因(GCK、HNF1A、HNF1B、HNF4A、ABCC8)。
  • P/LP携带者较非携带者诊断年龄更小、BMI更低、代谢控制更好,但临床异质性显著。
  • 35例(52.2%)不符合经典筛查标准(起病≤25岁且三代家族史)。
  • P/LP携带者的MODY概率评分更高(中位数75.5% vs 58.0%,P < .001),但早期胰岛素启动会大幅降低评分。

关键数值与推荐

  • P/LP变异检出率28.9%(67/232)。
  • 可操作基因变异占P/LP变异的95.5%(64/67)。
  • 不符合经典筛查标准的P/LP携带者占52.2%(35/67)。
  • MODY概率评分中位数:P/LP携带者75.5%,非携带者58.0%,P < .001。

临床怎么用

  • 对35岁前起病、BMI<30 kg/m²且胰岛自身抗体阴性的糖尿病患者应考虑基因检测。
  • 经典筛查标准和MODY概率计算器均不能单独作为排除单基因糖尿病的依据。
  • 检出可操作基因变异有助于指导精准治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Monogenic diabetes is often underdiagnosed because of limited genetic testing opportunities and varying screening criteria. OBJECTIVE: To investigate the genetic and clinical characteristics of monogenic diabetes in Japan and assess the utility of classical screening criteria and the maturity-onset diabetes of the young (MODY) probability calculator. DESIGN AND SETTING: This study included 232 probands with diabetes onset before age 35, body mass index <30 kg/m2, and negative islet autoantibodies, recruited from 2019 to 2024. Targeted sequencing of 11 causal genes was performed, followed by multiplex ligation-dependent probe amplification when indicated. RESULTS: Pathogenic or likely pathogenic (P/LP) variants were identified in 67 (28.9%) probands: 25 in GCK, 22 in HNF1A, 7 in HNF1B, 6 in HNF4A, 4 in ABCC8, and 1 each in NEUROD1, PDX1, and INSR. Of these, 64 (95.5%) carried P/LP variants in actionable genes potentially affecting treatment strategies (GCK, HNF1A, HNF1B, HNF4A, ABCC8). P/LP variant carriers were younger at diagnosis, had lower body mass index, and better metabolic control than noncarriers. However, clinical heterogeneity was substantial. Notably, 35 cases (52.2%) did not meet classical screening criteria of young onset (≤25 years) and a three-generation family history. Although MODY probability scores were higher in probands with P/LP variants (median: 75.5% vs 58.0%; P < .001), early insulin initiation substantially lowered the probability scores, warranting caution. CONCLUSION: We established a nationwide genetic testing platform and identified carriers of actionable variants, offering possibilities for precision medicine. Neither classical criteria nor the MODY probability calculator identified all monogenic cases, highlighting the need for broader genetic testing.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yoshiji S, Hasebe M, Tanaka D, et al. Genetic and Clinical Characteristics of Monogenic Diabetes in Japan: A Nationwide Study by the Japan Diabetes Society. J Clin Endocrinol Metab. 2026. PMID: 40853921. doi:10.1210/clinem/dgaf478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。